Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOFIBRATE (MICRONIZED) vs ANTARA (MICRONIZED)
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. It also increases apoproteins A-I and A-II, leading to increased HDL cholesterol.
Fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor alpha (PPARα). This leads to increased lipolysis and elimination of triglyceride-rich particles from plasma by inducing lipoprotein lipase activity and reducing production of apolipoprotein C-III.
Adjunctive therapy to diet for treatment of primary hypercholesterolemia or mixed dyslipidemia,Adjunctive therapy to diet for reduction of elevated triglycerides in patients with severe hypertriglyceridemia,Off-label: prevention of pancreatitis in patients with hypertriglyceridemia
Primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb) as an adjunct to diet,Hypertriglyceridemia (Fredrickson types IV and V) as an adjunct to diet
Fenofibrate (micronized) 145 mg orally once daily; alternatively 48 mg orally once daily to 145 mg orally once daily as tolerated.
Oral: 130 mg once daily with or without food. Capsules should be swallowed whole; do not crush or chew.
Terminal half-life of fenofibric acid is approximately 20 hours (range 19–27 hours) in adults, allowing once-daily dosing.
Terminal elimination half-life is approximately 15–17 hours (range 13–22 hours) in normolipidemic subjects; in hypertriglyceridemic patients, half-life may be prolonged up to 24–33 hours due to increased volume of distribution. Repeated dosing leads to steady state by about 4–5 days.
e GFR 30-59 m L/min/1.73 m2: reduce dose; maximum 48 mg/day. e GFR <30 m L/min/1.73 m2: contraindicated.
Severe renal impairment (e GFR <30 m L/min/1.73 m²): Use is not recommended. For patients with e GFR 30-60 m L/min/1.73 m², no dose adjustment is needed, but monitor renal function closely.
No FDA boxed warning.
Fenofibrate is classified as FDA Pregnancy Category C. In animal studies, it caused embryotoxicity and teratogenicity at maternal toxic doses. Human data are limited. First trimester: Unknown risk, avoid unless clearly needed. Second and third trimesters: May cause fetal harm; use only if benefit outweighs risk, as it may interfere with fetal lipid metabolism and development.
Fenofibrate is Pregnancy Category C. First trimester: No adequate human studies; animal studies show embryotoxicity at high doses. Second and third trimesters: Potential fetal harm due to lipid metabolism disruption; use only if benefit outweighs risk.
Fenofibrate (micronized) is primarily used to lower triglycerides and raise HDL-C; it is not first-line for LDL-C reduction. It can be combined with statins but increases risk of myopathy and rhabdomyolysis; monitor renal function and CPK. Avoid in severe renal impairment (Cr Cl <30 m L/min) and active liver disease. May potentiate oral anticoagulants; monitor INR closely. Also useful in treating hypertriglyceridemia-induced pancreatitis (TG >500 mg/d L).
Fenofibrate (micronized) is preferred over gemfibrozil when used with statins due to lower risk of myopathy. Monitor renal function (Cr) and hepatic enzymes (ALT/AST) at baseline and periodically. Avoid use in severe renal impairment (e GFR <30 m L/min) and active liver disease. May increase serum creatinine due to reduced creatinine secretion; stable elevations up to 0.2 mg/d L are common. Co-administration with bile acid sequestrants (e.g., cholestyramine) should be staggered by at least 2 hours. For patients with gallbladder disease, weigh risks due to increased biliary cholesterol saturation.
No interactions on record
No interactions on record
FENOFIBRATE (MICRONIZED) and ANTARA (MICRONIZED) are distinct pharmacological agents. FENOFIBRATE (MICRONIZED) belongs to the Fibrate class and is primarily used for Adjunctive therapy to diet for treatment of primary hypercholesterolemia or mixed dyslipidemiaAdjunctive therapy to diet for reduction of elevated triglycerides in patients with severe hypertriglyceridemiaOff-label: prevention of pancreatitis in patients with hypertriglyceridemia. ANTARA (MICRONIZED) belongs to the Fibrate class and is primarily used for Primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb) as an adjunct to dietHypertriglyceridemia (Fredrickson types IV and V) as an adjunct to diet. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. FENOFIBRATE (MICRONIZED) carries a safety status of Category A/B, whereas ANTARA (MICRONIZED) safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via glucuronidation; fenofibrate is a prodrug hydrolyzed by esterases to the active moiety fenofibric acid. Fenofibric acid is further metabolized by glucuronidation and excreted in urine. CYP450 enzymes are not significantly involved.
Primarily hepatic via glucuronidation and oxidation; CYP450 isoenzymes are not significantly involved. Fenofibrate is excreted as fenofibric acid and glucuronide conjugates, mainly in urine.
Renal: 60% (as fenofibric acid and glucuronide conjugates); Fecal: 25%; Biliary: minor.
Renal (approximately 70% of a dose is excreted in the urine, primarily as the glucuronide conjugate; less than 10% is excreted as unchanged drug in urine); fecal/biliary elimination accounts for about 20% (mainly as unchanged drug and metabolites via bile).
Fenofibric acid: 99% bound, primarily to albumin.
Approximately 99% bound to plasma proteins, mainly albumin (90–95%), with some binding to lipoproteins. Fenofibric acid has high affinity for albumin; saturation occurs at concentrations >300 µg/m L.
Apparent Vd: 0.9 L/kg, indicating distribution into total body water.
Apparent volume of distribution (Vd/F) is 0.9–1.0 L/kg (range 60–70 L for a 70 kg individual), indicating distribution into total body water; extensive tissue binding occurs (especially liver, kidney, and adipose tissue).
Oral (micronized): 66–81% under fed conditions; absorption increased by 35% with food.
Oral bioavailability of the micronized capsule is approximately 80–90% relative to the non-micronized formulation; food increases the rate and extent of absorption (AUC increases by 30–50%). Absorption is enhanced when taken with meals; absolute bioavailability compared to i.v. is not determined, but relative bioavailability is high.
Child-Pugh class A: use with caution; reduce dose by 50%. Child-Pugh class B or C: contraindicated.
Contraindicated in active liver disease or unexplained persistent liver function abnormalities. For Child-Pugh Class A or B: Use with caution; no specific dose adjustment guidelines available; monitor hepatic enzymes. Child-Pugh Class C: Contraindicated.
Not approved in children; safety and efficacy not established.
Safety and efficacy in pediatric patients (<18 years) have not been established; not recommended.
No specific dose adjustment recommended; start at low end of dosing range due to potential renal impairment.
No specific dose adjustments are required based on age alone; however, elderly patients may have reduced renal function; consider renal function monitoring and adjust as per renal guidelines.
None.
Should not be used in patients with preexisting gallbladder disease; may increase risk of cholelithiasis. Elevations in serum transaminases have occurred; monitor liver function tests. May increase serum creatinine; monitor renal function. Myopathy/rhabdomyolysis risk increased when used with statins or in patients with renal impairment. Avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²).
Severe renal impairment (e GFR <30 m L/min/1.73 m²), active liver disease including primary biliary cirrhosis, preexisting gallbladder disease, breastfeeding, known hypersensitivity to fenofibrate or fenofibric acid.
Take with a meal containing fat to enhance absorption. Avoid grapefruit juice as it may increase drug levels. Restrict alcohol intake to prevent worsening of hypertriglyceridemia.
Take with a meal containing some fat to enhance absorption. Avoid high-fat meals if also taking a statin to reduce additive muscle risk. No specific food restrictions but maintain a low-fat diet per lipid management.
Excretion into human milk is unknown. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued or fenofibrate avoided, especially if the infant has hypertriglyceridemia or other lipid disorders.
Excretion into human milk unknown; M/P ratio not established. Discontinue nursing or drug due to potential for serious adverse reactions in nursing infants.
No specific pharmacokinetic studies in pregnancy. Due to increased plasma volume and renal clearance, the dose may require adjustment, though standard dosing is typically followed. Caution in hepatic or renal impairment. Avoid concomitant statins due to increased risk of toxicity.
No specific dose adjustments recommended for pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure, but no data to guide dose modification. Use minimal effective dose if necessary.
Take with food to improve absorption and reduce GI upset.,Do not crush or chew the capsule; swallow whole.,Report unexplained muscle pain, tenderness, or weakness especially if accompanied by fever or malaise.,Avoid alcohol as it may increase triglyceride levels.,Attend regular blood tests to monitor liver function, kidney function, and lipid levels.,Inform all healthcare providers you are taking fenofibrate, especially before surgery.
Take with food to reduce gastrointestinal upset.,Do not crush or chew capsules; swallow whole.,Avoid alcohol while on this medication.,Report unexplained muscle pain, tenderness, or weakness to your doctor immediately.,You will need periodic blood tests to monitor liver and kidney function.,Inform your doctor if you have a history of gallstones, kidney disease, or liver disease.